I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision ...

Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly ...

Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...

Stock analysts at Leerink Partnrs increased their Q1 2025 earnings per share estimates for DexCom in a research report issued ...

Leerink Partnrs issued their Q1 2025 EPS estimates for Blueprint Medicines in a research note issued on Thursday, February ...

Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic ...

Goldman Sachs, Leerink and Evercore ISI acted as joint book running managers for the offering.Discover the Best Stocks and Maximize Your ...

Q4 2024 . Management View. CEO Chris Smith highlighted strong financial performance, with Q4 revenue reaching $172 million, ...

NeuroPace expects to use approximately $49.5 million of the net proceeds from the offering to repurchase 5,270,845 shares of the Company's common stock held by NeuroPace's significant stockholder, KCK ...

Vertex Pharmaceuticals Incorporated today announced management participation in three upcoming investor conferences. Stuart Arbuckle, Executive Vice President and Chief Operating Officer, and David ...

The trial data, which was reported on February 18, 2025, also suggested potential cardiac benefits from the therapy. The company mentioned that SGT-003 has been well-tolerated with no serious adverse ...